ID   USPC-ARK-1
AC   CVCL_IV72
SY   USPC ARK-1; USPC-ARK1; USC ARK-1; ARK-1
DR   cancercelllines; CVCL_IV72
DR   Wikidata; Q54991940
RX   PubMed=19920829;
RX   PubMed=21246534;
RX   PubMed=23891627;
RX   PubMed=26325104;
RX   PubMed=26625219;
CC   Population: African American.
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=23891627; PubMed=26325104).
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
DI   NCIt; C27838; Endometrial serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 19-12-24; Version: 10
//
RX   PubMed=19920829; DOI=10.1038/sj.bjc.6605448; PMCID=PMC2813756;
RA   El-Sahwi K.S., Bellone S., Cocco E., Cargnelutti M., Casagrande F.,
RA   Bellone M., Abu-Khalaf M., Buza N., Tavassoli F.A., Hui P.,
RA   Silasi D.-A., Azodi M., Schwartz P.E., Rutherford T.J., Pecorelli S.,
RA   Santin A.D.;
RT   "In vitro activity of pertuzumab in combination with trastuzumab in
RT   uterine serous papillary adenocarcinoma.";
RL   Br. J. Cancer 102:134-143(2010).
//
RX   PubMed=21246534; DOI=10.1002/cncr.25891; PMCID=PMC3128671;
RA   Varughese J., Cocco E., Bellone S., de Leon M., Bellone M.,
RA   Todeschini P., Schwartz P.E., Rutherford T.J., Pecorelli S.,
RA   Santin A.D.;
RT   "Uterine serous papillary carcinomas overexpress human
RT   trophoblast-cell-surface marker (Trop-2) and are highly sensitive to
RT   immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal
RT   antibody.";
RL   Cancer 117:3163-3172(2011).
//
RX   PubMed=23891627; DOI=10.1016/j.ajog.2013.07.020;
RA   English D.P., Bellone S., Cocco E., Bortolomai I., Pecorelli S.,
RA   Lopez S., Silasi D.-A., Schwartz P.E., Rutherford T.J., Santin A.D.;
RT   "Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications
RT   determine the sensitivity of uterine serous carcinoma cell lines to
RT   GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase
RT   (TORC1/2).";
RL   Am. J. Obstet. Gynecol. 209:465.e1-465.e9(2013).
//
RX   PubMed=26325104; DOI=10.1038/bjc.2015.306; PMCID=PMC4651122;
RA   Black J.D., Lopez S., Cocco E., Bellone S., Altwerger G., Schwab C.L.,
RA   English D.P., Bonazzoli E., Predolini F., Ferrari F., Ratner E.,
RA   Silasi D.-A., Azodi M., Schwartz P.E., Santin A.D.;
RT   "PIK3CA oncogenic mutations represent a major mechanism of resistance
RT   to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.";
RL   Br. J. Cancer 113:1020-1026(2015).
//
RX   PubMed=26625219; DOI=10.1038/bjc.2015.388; PMCID=PMC4705897;
RA   Black J.D., Lopez S., Cocco E., Bellone S., Altwerger G., Schwab C.L.,
RA   English D.P., Bonazzoli E., Predolini F., Ferrari F., Ratner E.,
RA   Silasi D.-A., Azodi M., Schwartz P.E., Santin A.D.;
RT   "Erratum to: PIK3CA oncogenic mutations represent a major mechanism of
RT   resistance to trastuzumab in HER2/neu overexpressing uterine serous
RT   carcinomas.";
RL   Br. J. Cancer 113:1641-1641(2015).
//